Anti-cancer perspectives of resveratrol: a comprehensive review

Abstract

Resveratrol (RVT) is well known for its chemo-preventive and therapeutic attributes against the various kinds of cancers such as breast, prostate, pancreatic, oral, brain, lung and liver. It has been found to inhibit glioblastoma cell growth, declining uPAR and its mediator ERK1/2, inhibiting the cell lines (EC-9706) growth and ADAM9 expression, up-regulating the lncRNAs and PPARγ, inhibition of MTA1 to modulate oncogenic miR-34a, miR-22 and miR-17, enhance the E-cadherin expression and decreased the expressions of Twist1 and vimentin, inhibiting ADAM9 expression, downregulation of ATP2A2 and ATP2A3 genes expressions in different breast cell lines, reduction in IL-6 and COX-2 expression, inhibition of Tax activity of LTR and HTLV-1 in SIRT1 deacetylase, suppression of epithelial-to-mesenchymal transition (EMT) and eEF1A expression and fracas interactions between TEAD and YAP and activation of Hippo/YAP signalling. Consequently, it can be suggested that RVT is a promising agent for treating aforementioned cancers due to its curing characteristics.